CEO: Jonas Frick
www.resistentia.se
Business:
Resistentia Pharmaceuticals AB, a biotechnology company founded in 1998, developing an allergy vaccine with human as well as veterinary applications. The method may offer new hope to allergy sufferers everywhere because it targets the source of the allergic reaction rather than the symptoms.
This is achieved by eliminating IgE, an antibody causing the release of histamine which triggers the allergic reactions for many individuals. The vaccine would be safer, easier to administer and more cost effective than other potential drug candidates currently under development.
Bankruptcy June, 2009
Contact:
Main office:
Resistentia Pharmaceuticals AB
Box 853
SE-751 08 Uppsala
Visitors address: Kungsängsvägen 25
Phone: +46 18 65 39 00
Fax: +46 18 65 39 10
info@resistentia.se